Mind-NRG ^Companies

Mind-NRG, based out of Switzerland, is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood - brain barrier through a receptor-mediated transport to reach its target in the brain. NRG-101 will be developed to treat disorders such as Parkinson's disease, Alzheimer's disease and schizophrenia. Mind-NRG will initially focus on conducting in vitro and in vivo experiments to further explore the mechanism of action of the peptide and to assess the activity of NRG-101 in a variety of relevant disease models.